UPDATE: Intra-Cellular Therapies stock soars 83% premarket after FDA approves schizophrenia treatment

    0
    32
    UPDATE: Intra-Cellular Therapies stock soars 83% premarket after FDA approves schizophrenia treatment

    Intra-Cellular Therapies Inc. shares
    ITCI, +128.54%
    soared 83% in premarket trade Monday, after the company said the U.S. Food and Drug Administration has approved a treatment for schizophrenia in adults. The New York-based biotech said the approval of its…
    Read More

    LEAVE A REPLY

    Please enter your comment!
    Please enter your name here